The mechanism of Hepatocyte-Targeting and safety profile of Phospholipid-Free small unilamellar vesicles

被引:0
|
作者
Fayez, Nojoud A. L. [1 ,3 ]
Bottger, Roland [1 ]
Brown, Jennifer [1 ]
Rouhollahi, Elham [1 ]
Li, Shyh-Dar [1 ,2 ]
机构
[1] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC V6T 1Z3, Canada
[2] Univ British Columbia, NanoMed Innovat Network NMIN, Vancouver, BC, Canada
[3] King Abdulaziz City Sci & Technol KACST, Riyadh, Saudi Arabia
基金
加拿大创新基金会; 加拿大自然科学与工程研究理事会; 加拿大健康研究院;
关键词
Phospholipid-Free Small Unilamellar Vesicles; (PFSUVs); Hepatocyte targeting; Apolipoproteins; Apolipoprotein AII (ApoA2); Scavenger receptor B-1 (SR-B1); SR-BI; DELIVERY; LIPOSOMES; RECEPTOR; ENDOCYTOSIS; INHIBITOR; TOXICITY; PATHWAYS; HDL;
D O I
10.1016/j.ijpharm.2022.122269
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Phospholipid-free small unilamellar vesicles (PFSUVs) composed of cholesterol and TWEEN80 (5:1 mol ratio), with an average diameter of 60 nm, displayed targeted delivery to the hepatocytes after intravenous (i.v.) injection. Here, we conducted a series of experiments to elucidate the hepatocyte targeting mechanism. The uptake of PFSUVs by HepG2 cells was increased by 3-fold in the presence of serum. The plasma protein corona adsorbed to PFSUVs was analyzed and subtypes of apolipoproteins were found enriched, specifically apolipoprotein AII (ApoA2). The cellular uptake was increased by 1.5-fold when the culture medium was supplemented with ApoA2, but not ApoC1 and ApoE. Furthermore, the cellular uptake of PFSUVs increased with increasing concentrations of ApoA2 in the medium and was almost completely blocked in the presence of BLT-1, an inhibitor for the scavenger receptor B-1 (SR-B1), which is a receptor for ApoA2. The data suggest that upon i.v. delivery, PFSUVs adsorbed plasma ApoA2 to the surface, which was recognized by SR-B1 expressed by the hepatocytes and then internalized. After internalization, mainly through the clathrin-mediated endocytosis, PFSUVs were found in the endosomes after 1-2 h post treatment and then lysosomes in 4 h. We also examined the cytotoxicity, hemolytic toxicity and complement activation of PFSUVs by incubating the formulation with HepG2 cells, red blood cells and human plasma, respectively, demonstrating no toxicity at concentrations higher than the therapeutic doses.
引用
收藏
页数:12
相关论文
共 6 条
  • [1] Phospholipid-Free Small Unilamellar Vesicles for Drug Targeting to Cells in the Liver
    Zhang, Wunan
    Bottger, Roland
    Qin, Zhu
    Kulkarni, Jayesh A.
    Vogler, Julian
    Cullis, Pieter R.
    Li, Shyh-Dar
    SMALL, 2019, 15 (43)
  • [2] Altering the intra-liver distribution of phospholipid-free small unilamellar vesicles using temperature-dependent size-tunability
    Vogler, Julian
    Bottger, Roland
    AL Fayez, Nojoud
    Zhang, Wunan
    Qin, Zhu
    Hohenwarter, Lukas
    Chao, Po-Han
    Rouhollahi, Elham
    Bilal, Nida
    Chen, Naliangzi
    Lee, Brandon
    Chen, Christine
    Wilkinson, Brayden
    Kieffer, Timothy J.
    Kulkarni, Jayesh A.
    Cullis, Pieter R.
    Witzigmann, Dominik
    Li, Shyh-Dar
    JOURNAL OF CONTROLLED RELEASE, 2021, 333 : 151 - 161
  • [3] Preparation of ready-to-use small unilamellar phospholipid vesicles by ultrasonication with a beaker resonator
    Klingler, Johannes
    Vargas, Carolyn
    Fiedler, Sebastian
    Keller, Sandro
    ANALYTICAL BIOCHEMISTRY, 2015, 477 : 10 - 12
  • [4] Investigation of the spontaneous transferability of a phospholipid-poly(ethylene glycol)-biotin derivative from small unilamellar phospholipid vesicles to magnetoliposomes
    De Cuyper, M
    Valtonen, S
    JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS, 2001, 225 (1-2) : 89 - 94
  • [5] Cell-free expression of a mammalian olfactory receptor and unidirectional insertion into small unilamellar vesicles (SUVs)
    Ritz, Sandra
    Hulko, Michael
    Zerfass, Christian
    May, Sylvia
    Hospach, Ingeborg
    Krasteva, Nadejda
    Nelles, Gabriele
    Sinner, Eva K.
    BIOCHIMIE, 2013, 95 (10) : 1909 - 1916
  • [6] DOPG small unilamellar vesicles function as nano-carriers targeting the clustered lectin-like oxidized LDL receptor (LOX-1) on the cell surface
    Ohta, Tetsuya
    Yamada, Risato
    Fujita, Satoshi
    Takahata, Taketoshi
    Shiba, Kohei
    Machida, Sachiko
    Tate, Shin-ichi
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2019, 51 : 327 - 336